Lynn Seely Sells 438 Shares of Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely sold 438 shares of Lyell Immunopharma stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $23.12, for a total value of $10,126.56. Following the completion of the transaction, the chief executive officer owned 81,721 shares of the company’s stock, valued at approximately $1,889,389.52. The trade was a 0.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Lynn Seely also recently made the following trade(s):

• On Wednesday, February 11th, Lynn Seely sold 7,455 shares of Lyell Immunopharma stock. The stock was sold at an average price of $23.39, for a total value of $174,372.45.

Lyell Immunopharma Price Performance

Lyell Immunopharma stock opened at $25.38 on Friday. Lyell Immunopharma, Inc. has a 12 month low of $7.65 and a 12 month high of $45.00. The company has a fifty day moving average price of $27.98 and a two-hundred day moving average price of $19.64. The company has a market cap of $539.07 million, a PE ratio of -1.10 and a beta of -0.14.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on LYEL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $20.00 to $45.00 in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $45.00.

Lyell Immunopharma News Summary

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Lyell dosed the first patient in PiNACLE, a Phase 3 head‑to‑head CAR‑T trial comparing rondecabtagene autoleucel (ronde‑cel / LYL314) to liso‑cel or axi‑cel in 2L relapsed/refractory large B‑cell lymphoma — a meaningful clinical and regulatory de‑risking step if the program advances. PiNACLE Phase 3 dosing
• Neutral Sentiment: Research and institutional positioning — the stock carries a mixed analyst profile (HC Wainwright upgraded LYEL to Buy and raised its PT previously) and significant institutional ownership (~66%), which can amplify moves but doesn’t change near‑term binary clinical risk. MarketBeat LYEL profile
• Negative Sentiment: Multiple insider sales this week — CEO Lynn Seely, COO Stephen Hill, insider Gary K. Lee and VP Veronica Sanchez Bulis reported sales on Feb. 10–11 that reduced their holdings (including a CEO sale of 7,455 shares on Feb. 11). Large or clustered insider selling can weigh on sentiment even if for personal/diversification reasons. SEC filings: CEO 2/11 Form 4 Gary Lee 2/11 Form 4 COO 2/11 Form 4 CEO 2/10 Form 4

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its holdings in Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Marshall Wace LLP bought a new stake in Lyell Immunopharma during the 2nd quarter valued at $94,000. Bridgeway Capital Management LLC acquired a new position in Lyell Immunopharma during the 2nd quarter worth $159,000. BBR Partners LLC bought a new position in shares of Lyell Immunopharma in the fourth quarter worth $210,000. Finally, Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma during the second quarter valued at $258,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.